Literature DB >> 16204025

Reduction of experimental human fibrosarcoma lung metastasis in mice by adenovirus-mediated cystatin C overexpression in the host.

Charlotte Kopitz1, Martina Anton, Bernd Gansbacher, Achim Krüger.   

Abstract

Tumor cell invasion and metastasis are associated with degradation of components of the extracellular matrix by different proteinases. Among those, papain-like cysteine proteases, such as cathepsin B, seem to play an important role, as they are associated with poor clinical outcome in different cancers. In this study, we tested whether cystatin C, a natural extracellular inhibitor of papain-like cysteine proteases, can inhibit metastasis when overexpressed at the tumor-host interface. Local overexpression of cystatin C in liver and lungs of CD1 nu/nu mice was achieved by gene transfer with a novel adenoviral construct, which also led to the presence of 60 ng/mL of cystatin C in the serum. Three days after gene transfer, these mice were challenged by i.v. inoculation of lacZ-tagged human fibrosarcoma cells (HT1080lacZ-K15), leading to the formation of experimental lung and liver metastases. In this model, formation of experimental metastatic foci correlated with expression of cathepsin B in lungs, whereas there was no correlation with metastasis to the liver. In mice overexpressing cystatin C, the number of lung metastases was significantly reduced by 92%, as compared with mice receiving control adenovirus. The efficacy of extravasation of HT1080lacZ-K15 cells into the liver was not affected, indicating the independence of this process from the activity of cysteine-cathepsins. The present report is the first evidence of successful reduction of metastasis by inhibition of cysteine-cathepsins by cystatin C overexpression in the host microenvironment. Furthermore, organ-specific protease expression during tumor-host cell interactions could affect the success of antiproteolytic intervention against metastasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16204025     DOI: 10.1158/0008-5472.CAN-05-1572

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Photodynamic therapy combined with a cysteine proteinase inhibitor synergistically decrease VEGF production and promote tumour necrosis in a rat mammary carcinoma.

Authors:  B Zsebik; K Symonowicz; Y Saleh; P Ziolkowski; A Bronowicz; G Vereb
Journal:  Cell Prolif       Date:  2007-02       Impact factor: 6.831

2.  Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.

Authors:  Fatma H Al-Awadhi; Brian K Law; Valerie J Paul; Hendrik Luesch
Journal:  J Nat Prod       Date:  2017-10-31       Impact factor: 4.050

3.  Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by hypoxia-inducible factor-1α.

Authors:  Florian Schelter; Birgit Halbgewachs; Petra Bäumler; Caroline Neu; Agnes Görlach; Florian Schrötzlmair; Achim Krüger
Journal:  Clin Exp Metastasis       Date:  2010-10-30       Impact factor: 5.150

Review 4.  Microbial inhibitors of cysteine proteases.

Authors:  Mateusz Kędzior; Rafał Seredyński; Jan Gutowicz
Journal:  Med Microbiol Immunol       Date:  2016-04-05       Impact factor: 3.402

5.  Role of L1 cell adhesion molecule (L1CAM) in the metastatic cascade: promotion of dissemination, colonization, and metastatic growth.

Authors:  Dirk Weinspach; Bastian Seubert; Susanne Schaten; Katja Honert; Susanne Sebens; Peter Altevogt; Achim Krüger
Journal:  Clin Exp Metastasis       Date:  2013-09-04       Impact factor: 5.150

6.  Differential cathepsin responses to inhibitor-induced feedback: E-64 and cystatin C elevate active cathepsin S and suppress active cathepsin L in breast cancer cells.

Authors:  Catera L Wilder; Charlene Walton; Valencia Watson; Fermin A A Stewart; Jade Johnson; Shelly R Peyton; Christine K Payne; Valerie Odero-Marah; Manu O Platt
Journal:  Int J Biochem Cell Biol       Date:  2016-08-31       Impact factor: 5.085

7.  Cystatin C deficiency promotes epidermal dysplasia in K14-HPV16 transgenic mice.

Authors:  Weifang Yu; Jian Liu; Michael A Shi; Jianan Wang; Meixiang Xiang; Shiro Kitamoto; Bing Wang; Galina K Sukhova; George F Murphy; Gabriela Orasanu; Anders Grubb; Guo-Ping Shi
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

8.  Soluble Expression of Recombinant Human Cystatin C and Comparison of the Ni Column and Magnetic Bead Purification.

Authors:  Yibin Zhang; Jian Zhao; Shiyu He; Xuni Cao
Journal:  Protein J       Date:  2020-02       Impact factor: 2.371

Review 9.  Cancer microenvironment and genomics: evolution in process.

Authors:  Stanley P Leong; Isaac P Witz; Orit Sagi-Assif; Sivan Izraely; Jonathan Sleeman; Brian Piening; Bernard A Fox; Carlo B Bifulco; Rachel Martini; Lisa Newman; Melissa Davis; Lauren M Sanders; David Haussler; Olena M Vaske; Marlys Witte
Journal:  Clin Exp Metastasis       Date:  2021-05-10       Impact factor: 5.150

10.  Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways.

Authors:  Barbara Wegiel; Thomas Jiborn; Magnus Abrahamson; Leszek Helczynski; Leo Otterbein; Jenny Liao Persson; Anders Bjartell
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.